Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	51D2007155	06/07/2022
Name of Provider or Supplier	**Street Address, City, State**	
Wv Drug Testing Laboratories	1531 Garfield Avenue, Parkersburg, WV	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An announced, on site, routine recertification survey was conducted at WV Drug Testing Laboratories Inc. on June 7, 2022, by the West Virginia Office of Laboratory Services. The laboratory was assessed for compliance with the Federal Clinical Laboratory Improvement Amendment (CLIA) regulations under 42 CFR 493. Specific deficiencies are explained below.
D5481	CONTROL PROCEDURES CFR(s): 493.1256(f)(g) (f) Results of control materials must meet the laboratory's and, as applicable, the manufacturer's test system criteria for acceptability before reporting patient test results. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on record review and interviews, the laboratory failed to ensure the external quality control (QC) met the requirements for acceptability, before releasing patient results, on 2 of 12 patient testing days in March 2022 for the TSQ Quantis LC/MS analyzer. Findings: 1. Review of QC records (February thru April 2022) for the TSQ Quantis LC/MS analyzer identified 2 days patient results were released in March when Level 1 QC did not meet the defined criteria for acceptability (3/17 and 3/29). 2. An interview with the general supervisor, 6/7/22 at approximately 12:00 PM, substantiated that 2 days in March had no acceptable Level 1 QC. 3. An exit interview with the laboratory director and general supervisor, 6/7/22 at approximately 1:00 PM, confirmed the findings.